Search results
Roth/MKM cuts Energous stock price target despite positive expectations By Investing.com
Investing.com· 13 hours agoOn Thursday, Roth/MKM maintained its Buy rating on Energous Corp (NASDAQ:WATT) but reduced the...
JPMorgan cuts Under Armour stock to underweight, slashes price target By Investing.com
Investing.com· 7 hours ago(NYSE:UAA), downgrading the stock from Neutral to Underweight. The firm also reduced the price ...
Immunocore (NASDAQ:IMCR) Price Target Cut to $88.00
ETF DAILY NEWS· 18 hours agoImmunocore (NASDAQ:IMCR – Free Report) had its price target lowered by Mizuho from $90.00 to $88.00 in a research note released on Monday, Benzinga reports ...
Scotiabank Cuts Nutrien (NYSE:NTR) Price Target to $66.00
ETF DAILY NEWS· 18 hours agoNutrien (NYSE:NTR – Free Report) had its target price cut by Scotiabank from $67.00 to $66.00 in a research report sent to investors ...
Walmart is nabbing Target’s ‘Tar-jay’ rep and Amazon’s delivery crowd as even the wealthy flock to...
Fortune via Yahoo Finance· 4 hours agoIt’s not an all-in endeavor for Target: The company also launched its own paid membership, Target...
BofA cuts Workday stock target, maintains buy rating By Investing.com
Investing.com· 15 hours agoOn Thursday, BofA Securities adjusted its outlook on Workday (NASDAQ:WDAY), a leading provider of...
Fate Therapeutics shares target cut by H.C. Wainwright on earnings outlook By Investing.com
Investing.com· 13 hours agoOn Thursday, an analyst from H.C. Wainwright adjusted the price target for Fate Therapeutics...
Mizuho Cuts The Hain Celestial Group (NASDAQ:HAIN) Price Target to $8.00
ETF DAILY NEWS· 18 hours agoThe Hain Celestial Group (NASDAQ:HAIN – Free Report) had its price objective cut by Mizuho from $10.00 to $8.00 in a report issued on Monday morning, Benzinga ...
Biggest inflation shock in decades has turned UK into nation of savers – report
PA Media: Money via Yahoo Finance· 2 hours agoThe “tumultuous period of price change” has changed what households do with their money, with...
Canaccord cuts Aptose Biosciences shares target, expects lead drug approval delay By Investing.com
Investing.com· 14 hours agoOn Thursday, Canaccord Genuity (TSX:CF) adjusted its price target on Aptose Biosciences...